• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 28, 2015

View Archived Issues

Fibrous optics: Chances look risk-worthy in liver space; BMS rolling the dice

Bristol-Myers Squibb Co. (BMS) made clear in its conference call on consensus-beating fourth quarter earnings that the firm will continue efforts to make its immuno-oncology presence "strong, deep and wide," but officials also made note of the newer push in antifibrotics via the whopper deal in November with Galecto Biotech AB and another earlier this month with the California Institute for Biomedical Research. Read More

Amgen's Neupogen faces U.S. headwinds: Earnings

Amgen Inc. reported after market close Tuesday that despite higher than expected fourth quarter profits, bolstered by strong sales of Enbrel (etanercept), sales of Neupogen (filgrastim) fell 11 percent year over year, driven by the impact of U.S. competition, inventory issues and foreign exchange rates. Read More

Lilly deal in hand, drug-device maker Zosano pulls trigger on IPO

The $49.5 million initial public offering (IPO) by drug-device maker Zosano Pharma Corp. was modest by comparison to 2014 blockbusters by the likes of Juno Therapeutics Inc. and Kite Pharma Inc. Read More

Revived bills impose DEA accountability, cut through regulatory tape

Enough with the inexplicable delays, lawmakers and health advocates said Tuesday as they discussed a bill that would force the Drug Enforcement Administration (DEA) to schedule new drugs in a predictable, more timely manner. Read More

Ascentage rising: Apoptosis candidate enters clinic in China

SHANGHAI – China-based Ascentage Pharma Group said APG-1387 is set to enter phase I trials as a new chemical entity under the Chinese 1.1 drug classification, a special category for innovative therapies not approved in other countries. Read More

More orphan drugs expected to find home in Asia Pacific

HONG KONG – The global orphan drugs market has been growing steadily, becoming big enough to garner the attention of big pharmaceutical companies, and rare disease patients in Asia Pacific will benefit from that trend. Read More

PTO's December 2014 guidance far from last word on Section 101 tests

Investors are little inclined to plow meaningful sums into companion diagnostics without patent protection, but the world of life science patents is in a state of flux due to at least two cases that have reached the Supreme Court. Read More

Financings

Intrexon Corp., of Germantown, Md., said it closed its public offering, including the full exercise by underwriters of their option to purchase an additional 562,500 common shares as overallotments. Read More

Stock movers

Read More

Other news to note

Biodelivery Sciences International Inc. (BDSI), of Raleigh, N.C., entered an assignment and revenue-sharing agreement with Meda AB, of Stockholm, under which Meda will transfer the marketing authorizations for Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain in the U.S. and the right to seek marketing authorizations for the product in Canada and Mexico back to BDSI, which originally licensed the rights to Meda in 2007. Read More

In the clinic

Envisia Therapeutics Inc., of Research Triangle Park, N.C., initiated an open-label phase IIa study to investigate the safety and tolerability of its lead candidate, ENV515, in patients with glaucoma. Read More

Pharma: Other news to note

Transcelerate Biopharma Inc., of Philadelphia, said two new members, Merck & Co. Inc., of Whitehouse Station, N.J., and Novo Nordisk A/S, of Bagsvaerd, Denmark, joined the biopharmaceutical nonprofit organization. Read More

Pharma: In the clinic

Bayer AG, of Leverkusen, Germany, said it inked a collaboration with the Population Health Research Institute and the Canadian Stroke Prevention Intervention Network to conduct the global phase III, indication-seeking trial, NAVIGATE ESUS, which will investigate the benefits of once-daily, oral factor Xa inhibitor rivaroxaban in patients with embolic stroke of undetermined source or cryptogenic stroke. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • The Nasdaq Stock Exchange headquarters in New York

    Omada, Caris arrivals continue med-tech IPO hot streak

    BioWorld MedTech
    Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe